2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

628. Aggressive Lymphomas: Cellular Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

1928 Humoral immune reconstitution and IVIG utilization after CD19 directed CAR-T therapy: A single center protocol and experience

Joshua SW Yi, MSc, Mohoammed Althobaiti, MD2, Harjot Singh Vohra, MD,MSc.,CCRP,MLT3, Carissa Choi4, Anca Prica, MD5, Sita Bhella, MD6, Tomohiro Aoki, MD, PhD7, Robert Kridel, MD8, Vishal Kukreti, MD9, Abi Vijenthira, MD, MS10, Chloe Yang, MD11, Michael Crump, MD12, John Kuruvilla, MD13, Inna Y Gong, MD, PhD14, Christine Chen, MHPE, MD, FRCPC15
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
4 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
5 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
6 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
8 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
10 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
11 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
12 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
13 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
14 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
15 Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Background: Delayed immune reconstitution and persistent hypogammaglobulinemia (hypo-IgG) after CD19 CAR-T contributes to increased infections and treatment morbidity. Intravenous (IVIG) or subcutaneous immunoglobulin (SCIG) are frequently used in this setting; yet practice patterns vary. Per our standard of care institutional guidelines, patients with pre-CAR-T serum IgG<4g/L receive empiric IVIG 400mg/kg prior to infusion and at Day 30, regardless of infection history, to cover the peak period of bacterial infection risk. Thereafter, monthly IVIG or weekly SCIG in 6-month blocks are recommended in those with peri-CAR-T infection or new-onset hypo-IgG with clinical infection. We aimed to evaluate this risk-adapted approach to Ig replacement in lymphoma patients.

Methods: We retrospectively reviewed 203 lymphoma patients treated with CD19 CAR-T from July 2023–April 2026. Diagnoses included large B-cell lymphoma (LCL) (n=109), transformed LCL (n=45), follicular lymphoma (n=22), and other subtypes (n=27). Most received axi-cel (83%); 82.3% had ≥2 prior lines; and 22% had a prior stem cell transplant. Serum IgG, IgM, and IgA levels, infections (incidence and type), CD19 B cell recovery (via peripheral blood flow cytometry) were tracked at baseline (prior to cell infusion), and up to 1-year post-CAR-T. Univariable logistic regression, chi-square, and Wilcoxon tests were performed when appropriate. Excluding baseline and Day 30, all analyses were limited to patients with ≥6 months follow-up.

Results: At baseline, 72/203(35.5%) patients had serum IgG<4g/L, 133/195(68.2%) IgM<0.4g/L, and 93/195(47.7%) IgA<0.7g/L. Sixty-nine (34.0%) and 104 (51.5%) patients received IVIG at baseline and Day 30, respectively. Univariate analysis showed that ≥2 lines of prior therapy (OR 3.9, 95% CI 1.7–8.9; p=0.002) and prior transplant (OR 3.0, 95% CI 1.5–5.9; p=0.001) were significantly associated with baseline IgG<4.

Subsequent analyses were restricted to patients with ≥6-month follow-up (n=103, median follow-up: 370 days; range 182–470).

Patients with baseline IgG<4g/L (n=36):

Thirty-three patients (91.7%) received protocol-directed empiric IVIG (pre-CAR-T and Day 30), with 21(63.6%) receiving Ig replacement beyond. In this group, only 1 patient (3.0%) achieved B-cell recovery by 6 months. At least one infection occurred in 10(30.3%), 11(33.3%), and 20(60.6%) patients at Days 0–30, 31–90, and >90, respectively. Correspondingly, infection rates were 33.8, 23.1, and 16.1 per 100 patient-months. Most infections were respiratory (54.5%).

Patients with baseline IgG≥4 g/L (n=67):

Twenty-six patients (38.8%) did not receive empiric baseline IVIG and never developed hypo-IgG. As per institutional guidelines, 11(42.3%) subsequently received Ig replacement for peri-CAR-T infection or perceived high infection risk. B-cell recovery was observed in 4 patients (15.4%) by 6 months. At least one infection occurred in 10(38.5%), 4(15.4%), and 12(46.2%) patients at days 0–30, 31–90, and >90, respectively. Corresponding infection rates were 50.7, 13.7, and 9.4 per 100 patient-months. Most infections were respiratory (48.6%). In contrast, 38(56.7%) patients did not receive empiric IVIG but subsequently experienced hypo-IgG, with onset by Day 30 in 22 patients (58.0%). Nineteen patients (50.0%) later received Ig replacement. Three patients (7.9%) achieved B-cell recovery by 6 months. One or more infections occurred in 13(34.2%), 11(28.9%), and 24(63.2%) patients at days 0–30, 31–90, and >90, respectively. Correspondingly, infection rates were 48.1, 21.4, and 12.9 per 100 patient-months. Most infections were respiratory (59.0%). Overall, 64(95.5%) patients with baseline IgG≥4g/L did not receive pre-CAR-T IVIG, consistent with institutional guidelines. Compared to patients with baseline IgG<4g/L who received empiric IVIG, there were no differences in the proportions with ≥1 infection at Days 0–30 (n=23, 35.9%; p=0.58), 31–90 (n=15, 23.4%; p=0.30), or >90 days (n=36, 56.3%; p=0.68). Similarly, infection rates per 100 patient-months did not differ at Days 0–30 (49.1, p=0.54), 31–90 (18.2, p=0.34), and >90 days (11.9, p=0.26).

Conclusions: Despite lower baseline IgG, patients receiving empiric IVIG had infection outcomes similar to those with IgG≥4 g/L who received no empiric IVIG. These findings suggest our risk-adapted guideline is pragmatic and may reduce unnecessary Ig replacement, although prospective validation is needed with larger sample sizes.

Joshua SW Yi, MSc: No relevant conflicts of interest to declare.